Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ramucirumab

- PMLiVE

AbbVie to acquire cancer biopharma Pharmacyclics for $21bn

Comes six months after the US firm pulled out of a $54bn deal with Shire

Bristol-Myers Squibb (BMS) building

BMS buys immunotherapy specialist Flexus in $1.2bn deal

And signs new cancer research partnership with Rigel

Eli Lilly HQ

Lilly delays filing of Lantus rival on safety concerns

Concerns over changes in liver fat detected in phase III trials

Eli Lilly HQ

Lilly sets back evacetrapib data deadline

Cholesterol drug trials extended by six months

EU flag

Half a million cancer patients in EU use targeted drugs

New data also shows breast and lung cancers are among the most treated in Europe

Roche Basel Switzerland

Roche acquires cancer biobank firm Signature Diagnostics

Marks Swiss firm's fifth deal this year to expand its molecular diagnostics business

- PMLiVE

Lilly and Boehringer claim first place for diabetes combination

US FDA backs Glyxambi as first combination of SGLT2 inhibitor and DPP-4 inhibitor.

Eli Lilly HQ

Lilly eyes pivotal trials for pain drug tanezumab in 2015

Drug was placed under clinical hold by FDA in 2010

- PMLiVE

Boehringer and Lilly sway NICE with new Jardiance data

Diabetes drug now backed to help glycaemic control in adults

- PMLiVE

CDF chair regrets undermining NICE

But Prof Clark says he wholeheartedly supports the Institute

- PMLiVE

Merck and Lilly enter Keytruda collaboration

Will research anti-PD-1 cancer therapy as part of combination treatment

Bristol Myers Squibb logo

BMS and Lilly to jointly research Opdivo combination

PD-1 inhibitor will be tested with Lilly's galunisertib

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links